Home » Market News » DirectorsTalk Highlights » The Biotech is ‘Harnessing the microbiome’s therapeutic potential’
4d Pharma Plc

The Biotech is ‘Harnessing the microbiome’s therapeutic potential’

A LifeSci Capital report presented a handful of key points about 4D Pharma.

Analyst Patrick Dolezal reported that LifeSci Capital initiated coverage on 4D Pharma Plc (LON:DDDD), a United Kingdom-based developer of biotherapeutics.

Dolezal highlighted five of the company’s advantages.

 

 

Founded in February 2014, 4D Pharma  is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.  All of 4D’s live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has completed a phase I study in Irritable Bowel Syndrome and has completed dosing in a phase I study in Paediatric Crohn’s Disease.  It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018. 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.